These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 36396878)
21. Peruvian Valuation of the EQ-5D-5L: A Direct Comparison of Time Trade-Off and Discrete Choice Experiments. Augustovski F; Belizán M; Gibbons L; Reyes N; Stolk E; Craig BM; Tejada RA Value Health; 2020 Jul; 23(7):880-888. PubMed ID: 32762989 [TBL] [Abstract][Full Text] [Related]
22. The EQ-5D-5L Valuation Study in Egypt. Al Shabasy S; Abbassi M; Finch A; Roudijk B; Baines D; Farid S Pharmacoeconomics; 2022 Apr; 40(4):433-447. PubMed ID: 34786590 [TBL] [Abstract][Full Text] [Related]
23. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets. Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577 [TBL] [Abstract][Full Text] [Related]
24. Analytical Considerations When Anchoring Discrete Choice Experiment Values Using Composite Time Trade-Off Data: The Case of EQ-5D-Y-3L. Mott DJ; Devlin NJ; Kreimeier S; Norman R; Shah KK; Rivero-Arias O Pharmacoeconomics; 2022 Dec; 40(Suppl 2):129-137. PubMed ID: 36396877 [TBL] [Abstract][Full Text] [Related]
25. The EQ-5D-3L valuation study for Bermuda: using an on-line EQ-VT protocol. Bailey H; Roudijk B; Brathwaite R Eur J Health Econ; 2024 Jul; ():. PubMed ID: 38982011 [TBL] [Abstract][Full Text] [Related]
26. Valuation of EQ-5D-5L in the Kingdom of Saudi Arabia: A National Representative Study. Al-Jedai A; Almudaiheem H; Al-Salamah T; Aldosari M; Almutairi AR; Almogbel Y; AlRuthia Y; Althemery AU; Alluhidan M; Roudijk B; Purba FD; Awad N; O'jeil R Value Health; 2024 May; 27(5):552-561. PubMed ID: 38342365 [TBL] [Abstract][Full Text] [Related]
27. Comparison of four value sets derived using different TTO and DCE approaches: application to the new region-specific PBM, AP-7D. Shiroiwa T; Murata T; Morii Y; Hoshino E; Fukuda T Health Qual Life Outcomes; 2024 Feb; 22(1):16. PubMed ID: 38341575 [TBL] [Abstract][Full Text] [Related]
28. Does Changing the Age of a Child to be Considered in 3-Level Version of EQ-5D-Y Discrete Choice Experiment-Based Valuation Studies Affect Health Preferences? Ramos-Goñi JM; Estévez-Carrillo A; Rivero-Arias O; Rowen D; Mott D; Shah K; Oppe M Value Health; 2022 Jul; 25(7):1196-1204. PubMed ID: 35379562 [TBL] [Abstract][Full Text] [Related]
29. Efficient Designs for Valuation Studies That Use Time Tradeoff (TTO) Tasks to Map Latent Utilities from Discrete Choice Experiments to the Interval Scale: Selection of Health States for TTO Tasks. Che M; Pullenayegum E Med Decis Making; 2023 Apr; 43(3):387-396. PubMed ID: 36866604 [TBL] [Abstract][Full Text] [Related]
30. How different are composite and traditional TTO valuations of severe EQ-5D-5L states? Xie F; Pullenayegum E; Gaebel K; Bansback N; Bryan S; Ohinmaa A; Poissant L; Johnson JA Qual Life Res; 2016 Aug; 25(8):2101-8. PubMed ID: 26875190 [TBL] [Abstract][Full Text] [Related]
31. International Valuation Protocol for the EQ-5D-Y-3L. Ramos-Goñi JM; Oppe M; Stolk E; Shah K; Kreimeier S; Rivero-Arias O; Devlin N Pharmacoeconomics; 2020 Jul; 38(7):653-663. PubMed ID: 32297224 [TBL] [Abstract][Full Text] [Related]
32. Comparison of Adult and Adolescent Preferences Toward EQ-5D-Y-3L Health States. Prevolnik Rupel V; Ramos-Goñi JM; Ogorevc M; Kreimeier S; Ludwig K; Greiner W Value Health; 2021 Sep; 24(9):1350-1359. PubMed ID: 34452716 [TBL] [Abstract][Full Text] [Related]
33. Time and lexicographic preferences in the valuation of EQ-5D-Y with time trade-off methodology. Lipman SA; Zhang L; Shah KK; Attema AE Eur J Health Econ; 2023 Mar; 24(2):293-305. PubMed ID: 35596831 [TBL] [Abstract][Full Text] [Related]
34. An experience- and preference-based EQ-5D-3L value set derived using 18 months of longitudinal data in patients who sustained a fracture: results from the ICUROS. Svedbom A; Borgstöm F; Hernlund E; Alekna V; Bianchi ML; Clark P; Diaz-Curiel M; Dimai HP; Jürisson M; Lesnyak O; McCloskey E; Sanders KM; Silverman S; Tamulaitiene M; Thomas T; Tosteson ANA; Jönsson B; Kanis JA Qual Life Res; 2023 Apr; 32(4):1199-1208. PubMed ID: 36495384 [TBL] [Abstract][Full Text] [Related]
35. Valuing EQ-5D-Y: the current state of play. Devlin N; Pan T; Kreimeier S; Verstraete J; Stolk E; Rand K; Herdman M Health Qual Life Outcomes; 2022 Jul; 20(1):105. PubMed ID: 35794607 [TBL] [Abstract][Full Text] [Related]
36. Self vs. other, child vs. adult. An experimental comparison of valuation perspectives for valuation of EQ-5D-Y-3L health states. Lipman SA; Reckers-Droog VT; Karimi M; Jakubczyk M; Attema AE Eur J Health Econ; 2021 Dec; 22(9):1507-1518. PubMed ID: 34611793 [TBL] [Abstract][Full Text] [Related]
37. The EQ-5D-3L Valuation Study in Pakistan. Malik M; Gu NY; Hussain A; Roudijk B; Purba FD Pharmacoecon Open; 2023 Nov; 7(6):963-974. PubMed ID: 37702988 [TBL] [Abstract][Full Text] [Related]
38. A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada. Xie F; Pullenayegum E; Gaebel K; Bansback N; Bryan S; Ohinmaa A; Poissant L; Johnson JA; Med Care; 2016 Jan; 54(1):98-105. PubMed ID: 26492214 [TBL] [Abstract][Full Text] [Related]
39. Exploring EQ-5D-Y-3L Experience-Based VAS Values Derived Among Adolescents. Åström M; Rolfson O; Burström K Appl Health Econ Health Policy; 2022 May; 20(3):383-393. PubMed ID: 35083734 [TBL] [Abstract][Full Text] [Related]
40. Estimating an EQ-5D-3L Value Set for Romania Using Time Trade-Off. Paveliu MS; Olariu E; Caplescu R; Oluboyede Y; Niculescu-Aron IG; Ernu S; Vale L Int J Environ Res Public Health; 2021 Jul; 18(14):. PubMed ID: 34299864 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]